A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the ASCO conference, the cancer field’s largest, kicks off, with oncologists and others tuning in from... Read more »
Human DNA holds secrets that, once uncovered, have led scientists to develop a number of treatments for disease. A slew of biopharmas and biotechs—not to mention national health systems—have hoovered up genetic data from millions of people in hopes of leveraging... Read more »
Most of the best-selling drugs worldwide today are antibodies, and in the three decades-plus since the first such drug was approved, makers of such treatments have begun endeavoring to design drugs to tackle ever more difficult classes of therapeutic targets.
Vancouver,... Read more »
Xconomy Insight is excited to offer two special webinars to our community this June. Sponsored by Eurofins, registration is free to all.
Screening Approaches for Reducing Attrition Due to Drug-induced Liver Injury (DILI) Early in Drug Discovery
Date: Wednesday, June... Read more »
COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list... Read more »
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine.
Moderna (NASDAQ: MRNA... Read more »
This was a disappointing week for at least two major drug makers. French firm Genfit reported a trial failure in an intensely competitive indication, and New York-based Bristol Myers Squibb encountered a delay when the FDA declined to review its experimental... Read more »
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal.
Last October, Alexion (NASDAQ: ALXN) struck a $930... Read more »
Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were... Read more »
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19.
National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauci praised the drug after... Read more »
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to drugs filed for accelerated approval. The... Read more »
An Immunomedics therapy for an aggressive form of breast cancer won FDA approval on Wednesday. It’s the company’s first regulatory nod, and it covers a product expected to become a blockbuster seller.
Morris Plains, NJ-based Immunomedics (NASDAQ: IMMU) developed the... Read more »
Veteran biotech executive Laura Shawver is taking over as CEO at Silverback Therapeutics, joining the cancer drug developer as it is poised to move its first compound into the clinic.
The Wednesday announcement comes three months after French firm Sanofi (NYSE:... Read more »